Back

Colchicine: who benefits?

31 August 2026 (08:51 - 09:09)
Organised by: Logo
Congress Presentation Part of: Assessing and treating 'residual risk' beyond low-density lipoproteins Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jean-Claude Tardif

Montreal Heart Institute, Montreal (Canada)

4 More presentations in this session

Presentation thumbnail
Optimal ways to identify high-risk cohorts beyond low-density lipoproteins: unmet high-risk patients
Doctor P. Ridker (Boston, US)
Slides Video
Presentation thumbnail
Targeting lipoprotein(a)
Professor B. Nordestgaard (Copenhagen, DK)
Slides Video
Presentation thumbnail
GLP1 agonist: for everyone?
Professor E. Michos (Baltimore, US)
Slides Video
Presentation thumbnail
Assessing and treating 'residual risk' beyond low-density lipoproteins - discussion
Video

Access the full session

Session thumbnail
Assessing and treating 'residual risk' beyond low-density lipoproteins
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 08:51 CET
You may be interested in
thumbnail
Congress Presentation
Inflammation reduction in patients with atherosclerotic cardiovascular disease
28 August 2026
thumbnail
Congress Presentation
Colchicine for the secondary prevention of cardiovascular diseases: a cumulative-dose meta-analysis of randomized controlled trials including 31,397 subjects worldwide
30 August 2025
thumbnail
Congress Presentation
Cardiovascular benefit of colchicine in relation to baseline risk
30 August 2024
thumbnail
Congress Presentation
Anti-inflammatory effects of atorvastatin and colchicine combination in patients with acute or chronic coronary syndrome undergoing coronary angiography and/or PCI
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources